Press "Enter" to skip to content

Anti-obesity Drugs Market 2019: Comprehensive Analysis by Top Key Companies, Industry Growth, Size, Share, Market Insights, Sales Volume and Forecast to 2024

Anti-obesity

The “Anti-obesity Drugs Market” 2019 report provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries. Anti-obesity Drugs Market report also aims to provide useful and comprehensive insights into current market trends and future growth scenarios. Anti-obesity Drugs market report contains information like SWOT analysis, business highlights, strength, weakness, threats and opportunities of industry.

Top Manufacturers of Anti-obesity Drugs Market Are:

  • Arena Pharmaceuticals
  • GlaxoSmithKline
  • Nalpropion Pharmaceuticals Inc.
  • F Hoffmann
  • La Roche
  • Vivus
  • Bayer AG
  • Novo Nordisk
  • Pfizer
  • Eisai

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999607

    Market Overview:

  • The anti-obesity drugs market is growing steadily with the gradual growth in the number of approvals from the US FDA and Europe EMA. North America, especially the United States, dominates this market, due to better healthcare services and high expenditure, followed by Europe. Till 2012, Xenical (orlistat) and generic phentermine were among the only approved drugs. However, the period between 2012 and 2016 saw high growth in the number of major pharmaceutical companies investing largely on clinical trials. However, there are still very fewer drugs in the late stage of development.
  • Owing to the less success rate and withdrawal among the centrally acting drugs, several of the major companies have considered the development of anti-obesity drugs as prohibitively risky and shifted the companies’ inclination toward broadening the scope of a diabetic portfolio into obesity. Since several companies have developed a strong relationship between Type 2 diabetes and obesity, it is often considered to be a low-risk strategy and minor investments in the R&D for potential anti-obesity drugs. Currently, the market is gradually growing its authority in the developing regions with the gradual approval of drugs, globally. However, it holds great potential with the aforementioned advantages, as several companies are targeting dual therapy mode for the treatment of obesity.
  • Scope of the Report:

  • An ideal anti-obesity drug would help in reducing sustained weight with minimal side effects. Mechanisms that control energy balance have considerable built-in redundancy, overlap with other physiological functions, and are subjected to social and psychological factors that restrict the effectiveness of pharmacological interventions. The anti-obesity drug market is segmented on the basis of the mechanism of action (peripherally acting and centrally acting anti-obesity drugs) and drug type (prescription and OTC drugs).

    Anti-obesity Drugs Market Report Answers the Following Questions:

    • What will the market size and the growth rate be in 2024?
    • What are the key factors driving the global Anti-obesity Drugs market?
    • What are the key market trends impacting the growth of the global Anti-obesity Drugs market?
    • What are the challenges to market growth?
    • Who are the key vendors in the global Anti-obesity Drugs market?
    • What are the market opportunities and threats faced by the vendors in the global Anti-obesity Drugs market?
    • Trending factors influencing the market shares of the relevant regions.
    • What are the key outcomes of the five forces analysis of the global Anti-obesity Drugs market?

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999607

    Key Market Trends:

    OTC Drugs Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period

    In the present scenario, the weight problem is a major concern, globally. The rising intake of junk food/fast food is resulting in declining healthiness worldwide. As mentioned earlier, obesity is one of the most prevalent problems faced by people of this century. According to WHO, in 2016, more than 1.9 billion adults, ranging between 18 years and older, were overweight. Out of the aforementioned numbers, over 650 million were obese. With intentions to offer weight loss solutions, the companies have developed a number of weight loss products, of which a considerable proportion are OTC drugs.

    In most countries, Orlistat is marketed as a prescription drug under the trade name Xenical, by Roche, and it is sold as an OTC drug under the trade name Alli, by GlaxoSmithKline, in the United Kingdom and the United States. Currently, the number of OTC drugs approved in the market is very less. However, the cost-effectiveness and ease of availability of OTC products are expected to propel the growth of the market.

    North America Captured the Largest Market Share and is Expected to Retain its Dominance

    North America dominated the global anti-obesity drugs market, with the United States accounting for the major contributor to the market. The primary factors driving the growth of the market studied are an increase in obese population and high healthcare spending. In the past few decades, several anti-obesity drugs are withdrawn from the market, due to reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. Majority of these medications are administered orally, and only one is administered subcutaneously. According to the data published by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity was 39.8% and affected about 93.3 million US adults in 2015-2016, hence propelling the anti-obesity drugs market.

    Market Dynamics: –

    • Drivers: (Developing regions and growing markets)
    • Limitations: (Regional, Key Player facing Issues, Future Barriers for growth)
    • Opportunities: (Regional, Growth Rate, Competitive, Consumption)

    The report provides key statistics on the market status of the Anti-obesity Drugs Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Anti-obesity Drugs.

    Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/13999607

    Report Objectives:

    • Analyzing the size of the Anti-obesity Drugs market on the basis of value and volume.
    • Accurately calculating the market segments, consumption, and other dynamic factors of different sections of the global Anti-obesity Drugs market.
    • Determining the key dynamics of the Anti-obesity Drugs market.
    • Highlighting significant trends of the Anti-obesity Drugs market in terms of manufacture, revenue, and sales.
    • Deeply summarizing top players of the Anti-obesity Drugs market and showing how they compete in the industry.
    • Studying industry processes and costs, product pricing, and various trends related to them.
    • Displaying the performance of different regions and countries in the global Anti-obesity Drugs market.

    Detailed TOC of Anti-obesity Drugs Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increase in Prevalence of Obesity
    4.2.2 Sedentary Lifestyle
    4.3 Market Restraints
    4.3.1 Availability of Alternative Treatment Options
    4.3.2 Side Effects of Drugs
    4.3.3 High Drug Development Costs
    4.4 Industry Attractiveness- Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 Mechanism of Action
    5.1.1 Peripherally Acting Anti-obesity Drugs
    5.1.2 Centrally Acting Anti-obesity Drugs
    5.2 Drug Type
    5.2.1 Prescription Drugs
    5.2.2 OTC drugs
    5.3 Geography
    5.3.1 North America
    5.3.1.1 United States
    5.3.1.2 Canada
    5.3.1.3 Mexico
    5.3.2 Europe
    5.3.2.1 United Kingdom
    5.3.2.2 Germany
    5.3.2.3 France
    5.3.2.4 Italy
    5.3.2.5 Spain
    5.3.2.6 Rest of Europe
    5.3.3 Asia-Pacific
    5.3.3.1 China
    5.3.3.2 Japan
    5.3.3.3 India
    5.3.3.4 Australia
    5.3.3.5 South Korea
    5.3.3.6 Rest of Asia-Pacific
    5.3.4 Middle East & Africa
    5.3.4.1 GCC
    5.3.4.2 South Africa
    5.3.4.3 Rest of Middle East & Africa
    5.3.5 South America
    5.3.5.1 Brazil
    5.3.5.2 Argentina
    5.3.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 Arena Pharmaceuticals
    6.1.2 GlaxoSmithKline
    6.1.3 Nalpropion Pharmaceuticals Inc.
    6.1.4 F Hoffmann-La Roche
    6.1.5 Vivus
    6.1.6 Bayer AG
    6.1.7 Novo Nordisk
    6.1.8 Pfizer
    6.1.9 Eisai

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Hydrocephalus Shunts Market 2019: Global Industry Trends, Future Growth, Regional Overview, Market Share, Size, Revenue, and Forecast Outlook till 2024

    Powered Wheelchairs Market Size, Share Research Report to 2019 | Industry Growth Share, Future Trends, Price, Top Key Players Review, and Global Analysis by Forecast 2024

    Diabetes Monitoring Devices Market 2019 | Qualitative Analysis of Top Key Companies, Global Industry Size & Share with CAGR, Regional Forecast to 2026

    Medical Monitor Market 2019 | Global Industry Size, Share, Explosive Factors of Key Players, Future Trends and Industry Growth Rate Forecast to 2023